GABAA receptor populations bind agonists and antagonists differentially and with opposite affinities.
Pretreatment of synaptosomal membranes with a diazo-coupling reagent and the presence of Cl- ions were used to differentiate high- and low-affinity populations of postsynaptic gamma-aminobutyric acid (GABAA) receptors. The super-low-affinity GABAA receptors were characterized by the enhancing effect of GABA on [3H]diazepam binding. The GABA antagonists 2-(3-carboxypropyl)-3-amino-4-methyl-6-phenylpyridazinium chloride (SR 95103) and 3-alpha-hydroxy-16-imino-5 beta-17-aza-androstan-11-one (R 5135) shifted and suppressed the dose-response curve of GABA on diazepam binding. SR 95103 displaced the lower affinity [3H]GABA binding with higher potency. Dissociation of the binding of the antagonist 2-(3-carboxypropyl)-3-amino-6-p-methoxyphenylpyridazinium bromide ([3H]SR 95531) was polyphasic. Displacing potencies of SR 95531 and GABA were examined on the major (85%) rapid and minor slower phases of dissociation separated kinetically. The slower phase corresponded to higher affinity binding of SR 95531 which was displaced by GABA with about 10 times less potency. Photoaffinity labeling with muscimol decreased the number of [3H]muscimol binding sites by 27%. It decreased the displacing potency of GABA by 72%, but not that of bicuculline methiodide. These findings can be explained by a preferential binding of antagonists to hydrophobic accessory sites around low-affinity GABAA receptors.
Maksay
G
G
Laboratory of Pharmacodynamics, Hungarian Academy of Sciences, Budapest.
D000345:Affinity Labels; D000731:Androstanes / Q000378:metabolism; D000818:Animals; D001378:Azasteroids / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D003975:Diazepam / Q000378:metabolism*; D003979:Diazonium Compounds / Q000494:pharmacology; D018756:GABA Antagonists; D008297:Male; D009118:Muscimol / Q000378:metabolism; D010777:Photochemistry; D011724:Pyridazines / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism*; D013425:Sulfanilic Acids / Q000494:pharmacology; D013570:Synaptic Membranes / Q000378:metabolism*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000345:Affinity Labels; D000731:Androstanes; D001378:Azasteroids; D003979:Diazonium Compounds; D018756:GABA Antagonists; D011724:Pyridazines; D011963:Receptors, GABA-A; D013425:Sulfanilic Acids; D009118:Muscimol; D005680:gamma-Aminobutyric Acid; C044796:2-(carboxy-3'-propyl)-3-amino-4-methyl-6-phenylpyridazinium chloride; C049853:gabazine; D003975:Diazepam; C032061:RU 5135; C000469:diazobenzenesulfonic acid